SpineAR SNAP (SyncAR Spine) is an AI-enabled medical device from Surgical Theater, Inc. that the U.S. FDA cleared through 510(k) K252054 on September 29, 2025. Its lead review panel is Neurology and its primary product code is SBF (Orthopedic Augmented Reality).
See also FDA-cleared AI neurology devices in 2025, all FDA AI clearances in 2025, top neurology AI devices.
Key facts
| Submission number | K252054 |
|---|---|
| Pathway | 510(k) |
| Date of final decision | |
| Company (FDA list) | Surgical Theater, Inc. |
| Lead review panel | Neurology |
| Primary product code | SBF — Orthopedic Augmented Reality |
| Applicant (openFDA) | Surgical Theater, Inc. |
| Applicant location | Beachwood, OH, US |
| Device class | Class 2 |
| Regulation number | 21 CFR 882.4560 |
| Decision code | SESE |
| Submission type | Traditional |
Source: FDA AI-Enabled Medical Devices list and openFDA.
What this means
A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. SpineAR SNAP (SyncAR Spine) went through this pathway (K252054).
openFDA lists it as a Class 2 device under 21 CFR 882.4560. Class II devices are moderate risk and are subject to general and special controls.
Product code SBF covers 5 devices on the FDA AI list. By decision date, this device is #4 of 5 under that code. Surgical Theater, Inc. has 1 AI-enabled device on the list, and the Neurology panel accounts for 73 in total.
Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.